Wendy Cuthbert, Viventia Biotech Inc.
Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
Advanced Squamous Cell Carcinoma of the Head and Neck
Carcinoma, Squamous Cell
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Head and Neck Cancer
Phase 2/Phase 3
The purpose of this study is to compare the safety and efficacy of Proxinium plus best
supportive care with best supportive care only for patients with squamous cell head and neck
Ages Eligible: 18 Years
Accepts Healthy Volunteers:
The patient must be 18 years of age or older.
The patient must have squamous cell carcinoma of the head and neck.
The squamous cell carcinoma must be Ep-CAM positive.
ECOG performance status of 0, 1, 2 or 3.
12 week life expectancy
The patient must have received therapy for their primary disease (eg, surgery and/or
radiotherapy, chemo-radiotherapy or chemotherapy).
The patient must have been diagnosed with persistent or recurrent disease or a second
The patient's disease must be refractory.
There must be at least 2 weeks between the last dose of chemotherapy or radiotherapy
and receiving study drug or 4 weeks between the last dose of an experimental drug and
receiving study drug.
The patient must have adequate hepatic function [alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) ≤2.5 × upper limit of normal (ULN) and bilirubin
level ≤1.5 × ULN].
The patient must have adequate renal function (serum creatinine < 1.5 × ULN).
The patient must have the following hematological values: granulocytes ≥1500/μL,
platelets ≥75 000/μL and hemoglobin >8 g/dL.
The patient must have prothrombin time and partial thromboplastin time within normal
• Women of childbearing potential and male patients must agree to use a highly effective
The patient has clinically significant distant metastases.
The patient is eligible to have surgical resection or radiotherapy,
chemo-radiotherapy or chemotherapy.
The patient has a nasopharyngeal tumour.
The patient has AIDS, hepatitis C or hepatitis B.
The patient has clinically significant renal or hepatic disease.
Tumors are prone to bleeding.
The patient is pregnant or lactating.
The patient requires 'blood thinning' medications and can not safely discontinue the
The patient is currently enrolled in another clinical trial.
Back to Search Results
Information objtained from ClinicalTrials.gov, on
10/25/2014. For additional information about
this and other clinical trials,
Please refer to this study by its ClinicalTrials.gov identifier: